Trevi Therapeutics(NASDAQ) TRVI

Trevi Therapeutics makes medicine for people with severe coughing. Its main product helps patients with lung diseases breathe easier. This treatment targets the brain to quiet the cough.

Targeting Debilitating Cough Conditions

• IPF Chronic Cough: Oral therapy for patients with idiopathic pulmonary fibrosis, a progressive disease that causes lung scarring.
• Refractory Chronic Cough: Investigational drug for adults whose coughing persists despite treating other underlying medical issues.
• Non-IPF ILD: Potential treatment for chronic cough associated with a variety of interstitial lung diseases beyond pulmonary fibrosis.

Recent Clinical and Corporate Milestones

• Announced positive topline results from the Phase 2b CORAL trial for IPF-related chronic cough in June 2025.
• Initiated the Phase 3 OCEAN-1 trial and the Phase 2b LAKE clinical trial during the second quarter of 2026.
• Raised approximately $162.3 million in net proceeds through a public stock offering in April 2026.
• Reported positive data from the Phase 2a RIVER proof-of-concept trial for refractory chronic cough in March 2025.
• Established an agreement to initiate a Phase 3 OCEAN-2 trial during the third quarter of 2026.

What Makes Trevi Stand Out?

The company uses a dual-action mechanism that targets opioid receptors in the brain to control the cough reflex arc. This approach helps reduce coughing while blocking receptors typically associated with the risk of drug abuse.

The Financial Scorecard

• Net loss was $17.8 million for the three-month period ended June 30, 2026, compared to $12.3 million for the same period in 2025.
• Research and development expenses rose to $15.2 million for the three-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $318.9 million as of June 30, 2026.
• Public stock offerings in April 2026 and June 2025 provided aggregate gross proceeds of over $288 million.
• Management expects that current cash resources will fund operating expenses and capital requirements into 2030.

Bottom Line

Trevi has evolved into a late-stage clinical company focusing on high-need respiratory conditions. It is currently advancing its lead candidate through multiple pivotal trials to reach potential regulatory approval and commercial launch.